X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MERCK LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA MERCK LTD GSK PHARMA/
MERCK LTD
 
P/E (TTM) x 67.6 47.9 141.1% View Chart
P/BV x 13.6 7.2 188.0% View Chart
Dividend Yield % 1.1 0.4 270.9%  

Financials

 GSK PHARMA   MERCK LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
MERCK LTD
Dec-16
GSK PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs2,7601,060 260.4%   
Low Rs2,040623 327.4%   
Sales per share (Unadj.) Rs339.0632.4 53.6%  
Earnings per share (Unadj.) Rs41.445.7 90.6%  
Cash flow per share (Unadj.) Rs45.962.3 73.7%  
Dividends per share (Unadj.) Rs35.0011.00 318.2%  
Dividend yield (eoy) %1.51.3 111.6%  
Book value per share (Unadj.) Rs242.9388.8 62.5%  
Shares outstanding (eoy) m84.7016.60 510.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.11.3 532.0%   
Avg P/E ratio x57.918.4 314.8%  
P/CF ratio (eoy) x52.313.5 387.2%  
Price / Book Value ratio x9.92.2 456.6%  
Dividend payout %84.524.1 351.2%   
Avg Mkt Cap Rs m203,28013,969 1,455.2%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m5,2341,487 352.1%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m28,71510,498 273.5%  
Other income Rs m545242 225.0%   
Total revenues Rs m29,26010,741 272.4%   
Gross profit Rs m5,0591,135 445.6%  
Depreciation Rs m380276 137.9%   
Interest Rs m20-   
Profit before tax Rs m5,2221,102 473.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892343 551.1%   
Profit after tax Rs m3,508759 462.2%  
Gross profit margin %17.610.8 162.9%  
Effective tax rate %36.231.1 116.3%   
Net profit margin %12.27.2 169.0%  
BALANCE SHEET DATA
Current assets Rs m21,8156,410 340.3%   
Current liabilities Rs m15,9998,828 181.2%   
Net working cap to sales %20.3-23.0 -87.9%  
Current ratio x1.40.7 187.8%  
Inventory Days Days6458 110.2%  
Debtors Days Days1938 48.7%  
Net fixed assets Rs m12,4751,406 887.0%   
Share capital Rs m847166 510.2%   
"Free" reserves Rs m19,7266,286 313.8%   
Net worth Rs m20,5736,455 318.7%   
Long term debt Rs m60-   
Total assets Rs m39,4758,828 447.1%  
Interest coverage x2,612.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.71.2 61.2%   
Return on assets %8.98.6 103.4%  
Return on equity %17.111.8 145.0%  
Return on capital %26.217.1 153.7%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m564959 58.8%   
Fx outflow Rs m7,4292,612 284.4%   
Net fx Rs m-6,865-1,653 415.3%   
CASH FLOW
From Operations Rs m4,7281,070 441.7%  
From Investments Rs m-1,042-750 139.0%  
From Financial Activity Rs m-3,066-150 2,047.0%  
Net Cashflow Rs m620171 362.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 51.8 97.9%  
Indian inst/Mut Fund % 10.2 18.2 56.0%  
FIIs % 23.8 1.0 2,380.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 29.1 52.9%  
Shareholders   102,036 28,591 356.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

GSK PHARMA at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

GSK PHARMA share price has hit a 52-week high. It is presently trading at Rs 3,350. BSE 500 Index is up by 0.8% at 15,497. Within the BSE 500, GSK PHARMA (up 2.0%) and IL&FS TRANSPORTATION (up 8.0%) are among the top gainers, while top losers are TECHNO ELECTRIC and P&G HYGIENE.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS